Jonathan Alicea

Despite the increasing push for using HCV-positive organs to expand the donor pool, hundreds of livers allografts from donors are still not being used in transplantation.

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

Proactive efforts throughout the pandemic must be made to ensure this gap in primary and preventative care can be filled.

The UK’s regulatory agency is advising those with a history of severe allergies not to get vaccinated pending investigations of 2 severe adverse events.

New ASH data demonstrates that RUDAS and MoCA scores are associated with highest level of education.

Luspatercept added to best supportive care reduced transfusion burden while TranQol and SF-36 HRQoL scores were maintained through Week 48.

A Phase I study reports on the safety and potential efficacy of lintuzumab Ac225 plus CLAG-M for relapsed/refractory acute myeloid leukemia.

In data presented at ASH 2020, FT-4204 shows early potential in being safe, efficacious treatment for sickle cell disease.

Analyses of vital sign changes from the 6-minute walk test may be indicative of cardiopulmonary function and potential survival among patients with sickle cell disease.

A study finds that children with cognitive or emotional deficits trended towards an increased healthcare utilization.

Patients with baseline PROMIS-57 scores worse than population norms reported clinically significant improvements in 6 of 8 domains at 12 months post-treatment.

Patients with acute myeloid leukemia or myelodysplastic syndromes are at especially increased risk for increased disease severity and death.

Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.

High levels of fetal hemoglobin have previously been linked to the mitigation of morbidity and mortality of sickle cell anemia.

Those without prior exposure to venetoclax experienced the most benefit.

This combination therapy may have a few advantages over standard corticosteroid regimens.

Patients with normal eGFR increased from 60% at baseline to 80% at 3 years following procedure.

Adherence was also reported to be high, yet variable, with use of wireless pillboxes and video-based observed therapy.

2020 was the year when regulators, clinicians, and patients had no choice but to embrace the concept of wearable monitoring devices. But it’s been a long time coming for the technology class.

Pediatric patients who initiated insulin pump therapy within 6 months of diagnosis demonstrated better cardiovascular risk profiles than those who delayed treatment.

New data shows a large shift from mortality due bacterial infection to other sickle cell disease causes, treatment complications, or non-related comorbidities.

Patients with hematological disorders like sickle cell disease or β-thalassemia are at high risk for HCV infection as a result of frequent transfusions.

Literature is scarce in identifying and characterizing risk of post-operative diabetes mellitus among patients with pancreatic cystic lesions.

Guidance based on procalcitonin concentration levels may useful in reducing duration of antibiotic treatment for sickle cell patients with acute chest syndrome.

To date, 3 vaccine candidates with favorable safety profiles show promise in offering protection against COVID-19.

The AI-based technology is expected to augment telehealth and remote services for a vast majority of cardiological cases.

Telemedicine has been associated with improved access to care and clinical efficiency without sacrificing diagnostic accuracy.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

Investigators used CDC HCV infographic posters to remind healthcare providers and offer educational resources about screening.